Across TCGA pan-cancer cohorts, ERCC6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ERCC6 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERCC6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ERCC6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ERCC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.537	<.001	47	view →
PDAC	DFS	Median	IV	0.234	0.766	.026	9	view →
LUAD	DFS	Tertile	II,III,IV	0.682	0.990	.021	8	view →
LSCC	OS	Median	All	0.814	0.922	.010	7	view →
HNSC	DFS	Median	All	0.982	0.923	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ERCC6 tumor-vs-normal RNA expression · all ERCC6 data types